Takeda Cuts 243 Neuro Reps as Trintellix Patent Cliff Looms
By FieldPulse Editorial · March 27, 2026
Tags: Layoffs, CNS, Territory, Neuroscience
Takeda is eliminating ~243 US neuroscience field positions — including ~190 sales specialists and district managers across 47 states — ahead of Trintellix's December 2026 patent expiration. The company says it's creating 400+ new launch roles.
Takeda Pharmaceutical is cutting 243 US neuroscience field positions , including approximately 190 sales specialists and district managers across 47 states , as the company prepares for generic competition against Trintellix (vortioxetine) , its flagship depression and cognitive function treatment.
Trintellix's patent expires in December 2026 , making this restructuring one of the most clearly telegraphed LOE-driven workforce reductions in recent memory.
The cuts are not a surprise — they follow the classic pharma playbook of right-sizing a field force ahead of a loss of exclusivity (LOE) event.
What makes Takeda's move notable is the scale relative to the brand, the company's framing of the restructuring, and the simultaneous announcement of 400+ new commercial roles tied to upcoming launches.
The Trintellix LOE Reality Trintellix has been Takeda's primary neuroscience commercial asset in the US, with annual revenue in the range of $1.5-2 billion.
The drug differentiates from other antidepressants through its multimodal mechanism — combining serotonin reuptake inhibition with activity at multiple serotonin receptor subtypes — and its FDA-approved claim for cognitive improvement in major depressive disorder, a unique label advantage that gave reps a genuine clinical talking point.
But the December 2026 patent expiration means that generic vortioxetine will likely be available by early 2027, and generic manufacturers have already been positioning to enter the market.
Once generics hit, Trintellix revenue will erode rapidly — the typical brand retention curve shows 80-90% volume loss within 12-18 months of generic entry in the antidepressant category.
Maintaining a full neuroscience field force through that erosion period makes no financial sense, which is why Takeda is acting now rather than waiting for the patent to actually expire.
The nine-month lead time gives affected employees notice (and WARN Act compliance where applicable) while allowing Takeda to redirect c.
Source: https://www.fiercepharma.com/pharma/takeda-cuts-243-us-workers-generic-competition-looms-trintellix